(5) ¿ÍÀÎÀå ¿ù³Ó
CIKrkYKygTJfFZe 402
I've been cut off http://xnxxxxx.in.net/ xnnn  The primary endpoint of the study is to compare the annualised rate of moderate and severe COPD exacerbations during a 52-week treatment period, with the aim of demonstrating the superiority of Flutiform (fluticasone and formoterol)over formoterol in a pressurised metered dose inhaler. Mundipharma hopes to recruit 1,530 patients. 
Emmett 2020-01-12 20:18:20

ȸ»ç¼Ò°³ | ã¾Æ¿À½Ã´Â ±æ | ÀÎÁõ³»¿ëº¸±â